← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,606	-21	-1%	$133B
2	2 Amgen AMGN $238B	1,062	+30	+3%	$68.7B
3	3 Eli Lilly LLY $1.13T	974	-1	-0.1%	$41.2B
4	4 Becton Dickinson BDX $52.4B	804	+8	+1%	$16.3B
5	5 Teva Pharmaceutical Industries Limited TEVA $48.1B	705	-39	-5%	$16.5B
6	6 McKesson MCK $116B	703	+25	+4%	$25.1B
7	7 Conagra Brands CAG $6.84B	585	-21	-3%	$8.7B
8	8 Novo Nordisk NVO $174B	425	+14	+3%	$6.3B
9	9 DaVita DVA $11.9B	414	-17	-4%	$10.4B
10	10 Regeneron Pharmaceuticals REGN $82.8B	414	+43	+12%	$24B
11	11 AstraZeneca AZN $261B	343	+12	+4%	$6.81B
12	12 ResMed RMD $33.8B	322	+9	+3%	$4.53B
13	13 Herbalife HLF $1.52B	303	+23	+8%	$7.04B
14	14 Accendra Health ACH $24M	227	-1	-0.4%	$2.18B
15	15 West Pharmaceutical WST $26.9B	205	+8	+4%	$2.57B
16	16 DELISTED WW International WW	180	+12	+7%	$2.15B
17	17 Opko Health OPK $1.2B	155	+24	+18%	$571M
18	18 Dr. Reddy's Laboratories RDY $10.8B	141	-8	-5%	$837M
19	ARNA 19 DELISTED Arena Pharmaceuticals Inc ARNA	140	+6	+4%	$604M
20	20 Medifast MED $137M	140	-4	-3%	$316M
21	21 Tootsie Roll Industries TR $2.93B	138	-2	-1%	$445M
22	22 MannKind Corp MNKD $990M	133	-2	-1%	$371M
23	23 Fresenius Medical Care FMS $11.8B	130	-17	-12%	$569M
24	24 Lexicon Pharmaceuticals LXRX $725M	102	-1	-1%	$1.12B
25	25 Madrigal Pharmaceuticals MDGL $10.6B	84	0	0%	$320M